Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment

Catheterization and Cardiovascular Interventions

Volumn 49, Issue 2, 2000, Pages 177-180

  Vahdat, Bruno ^a   Canavy, Isabelle ^b   Fourcade, Laurent ^b   Garcia, Eric ^b   Quilici, Jacques ^b   Bonnet, Jean Louis ^b   Bory, Michel ^b  

^a TIMONE HOSPITAL   (France)

^b NONE

Author keywords

Abciximab; Angioplasty; Cerebral vascular accident; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEPARIN; TICLOPIDINE;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLOOD CELL COUNT; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; CASE REPORT; COMPLETE HEART BLOCK; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART CATHETERIZATION; HEART INFARCTION; HUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CEREBRAL HEMORRHAGE; CORONARY ANGIOGRAPHY; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA; THROMBOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033959716     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-726X(200002)49:2<177::AID-CCD13>3.0.CO;2-J     Document Type: Article

References (18)

1. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991;614:193-213.
2. Coller BS, Anderson KM, Weisman HF. The anti-GPIIb-IIIa agents: fundamental and clinical aspects. Haemostasis 1996;26 (Suppl 4):285-293.
3. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
4. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349: 1429-1435.
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
6. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
7. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM, for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-2890.
8. Rao AK, Pratt C, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML, for the TIMI Investigators. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patient treated with recombinant tissue plasminogen activator and streptokinase. J Am Cardiol 1988;11:1-11.
9. Califf RM, Lincoff AM, Tcheng JE, Topol EJ. An overview of the results of the EPIC trial. Eur Heart J 1995;16:43-49.
10. ™) therapy for acute myocardial infarction. Cathet Cardiovasc Diagn 1998;44:313-316.
11. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.
12. Joseph T, Marco J, Gregorini L. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty. Clin Cardiol 1998;21:851-852.
13. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the prevention of ischemic complications trial. Am J Cardiol 1995;75:559-562.
14. Ammar T, Sarier K, Coller BS. Activated clotting time of heparinized blood is increased by in vitro platelet glycoprotein IIb/IIIa receptor blockade with antibody c7E3Fab (abstract). Thromb Haemostas 1995;73:1313.
15. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderck TM, Runyon JP. Abciximab associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-1163.
16. Bednar B, Bednar RA, Cook JJ, Bollag DM, Chang CT, Gaul SL, McQueeney PA, Egbertson MS, Hartman GD, Holahan MA, Lynch JJ, Gould RJ. Drug-dependent antibodies against GPIIb/IIIa induce thrombocytopenia. Circulation 1996;94 (Suppl I):I-98.
17. Aster RH. Heparin-induced thrombocytopenia. N Engl J Med 1995;332:1374-1376.
18. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991;337:774-776.